去纤维钠属于医保报销药品吗？

(Defibrotide) is currently recognized as the most promising new drug for the treatment of hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT). Based on its anticoagulant, fibrinolysis-promoting, and anti-inflammatory effects, Richardson et al. first explored its application in the treatment of HVOD after HSCT. This study included 19 sHVOD patients. The dosage of defibrotide sodium (defibrinoside) is 5~60 mg/kg per day, intravenous infusion, and the median use time is 15 days (2-61 days). The results showed that 42% of patients achieved complete remission (CR), and the overall survival (os) rate 100 days after transplantation reached 32%, and patients could tolerate defibrination well. Since then, many clinical trials have confirmed the effectiveness of defibrotide sodium (defibrotide) in the treatment of HVOD.

So is defibrotide sodium (defibrinoside) a drug reimbursed by medical insurance?

The answer is no. Because defibrotide sodium (defibrotide) is not currently on the market in China, and it has not been included in the national medical insurance catalog, patients will not be able to enjoy the benefits brought by medical insurance in the short term. However, I believe that with the joint efforts and promotion of all parties, defibrotide sodium (defibrotide) will be launched in China as soon as possible and will be covered by medical insurance.

The recommended dose of defibrotide sodium (Defibrotide) for adult and pediatric patients is 6.25 mg/kg given every 6 hours as a 2-hour intravenous infusion. The dose should be based on the patient's baseline weight, which is defined as the patient's weight before the HSCT preparation protocol. Give sodium defibrate (defibrotide) for a minimum of 21 days. If signs and symptoms of hepatic VOD have not resolved after 21 days, continue defibrination until resolution of VOD or up to a maximum of 60 days.

Defibrotide sodium (Defibrotide) must be diluted before infusion. Prior to administration of defibrotide, confirm that the patient is not experiencing clinically significant bleeding and is hemodynamically stable on no more than one vasopressor. Administer defibrotide by constant intravenous infusion over a 2-hour period. Use an infusion set equipped with a 0.2 micron in-line filter to administer the diluted defibrinated sodium (defibrotide) solution. Flush the intravenous administration line (peripheral or central) with 5% Dextrose Injection, USP, or 0.9% Sodium Chloride Injection, USP, before and immediately after administration. Patients should note: (Defibrotide) should not be co-administered with other intravenous drugs at the same time in the same intravenous line.

Recommended related hot articles: /newsDetail/83341.html